Nephrotic syndrome in childhood

Lancet

Volumn 362, Issue 9384, 2003, Pages 629-639

  Eddy, Allison A ^a,b   Symons, Jordan M ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ALPHA ACTININ; BETA4 INTEGRIN; CALCINEURIN INHIBITOR; CHLORAMBUCIL; COLLAGEN TYPE 4; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DIAMORPHINE; GLUCOCORTICOID; GOLD; IMMUNOGLOBULIN E; INTERFERON; LEVAMISOLE; LITHIUM; MEMBRANE PROTEIN; MERCURY; METHYLPREDNISOLONE; MIZORIBINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEPHRIN; NONSTEROID ANTIINFLAMMATORY AGENT; NUCLEAR PROTEIN; PAMIDRONIC ACID; PENICILLAMINE; PROTEIN; SLIT PROTEIN; STEROID; TRANSFORMING GROWTH FACTOR;

AGRANULOCYTOSIS; BACTERIAL INFECTION; BRAIN DISEASE; CHILDHOOD; CLINICAL TRIAL; CONFERENCE PAPER; CONGENITAL NEPHROTIC SYNDROME; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG USE; EDEMA; FATALITY; GENE IDENTIFICATION; GENE MUTATION; GENETIC ANALYSIS; GENETIC CODE; GENETIC DISORDER; GLOMERULAR DYSFUNCTION; GLOMERULOSCLEROSIS; GONADAL DISEASE; HISTOLOGY; HUMAN; HYPERLIPIDEMIA; IDIOPATHIC DISEASE; IMMUNOADSORPTION; IMMUNOPATHOLOGY; INFECTION; KIDNEY FAILURE; LEUKOPENIA; LIVER TOXICITY; LOW DRUG DOSE; LYMPHOID CELL; MEMBRANOUS GLOMERULONEPHRITIS; NEOPLASM; NEPHROTIC SYNDROME; NEPHROTOXICITY; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PLASMAPHERESIS; PODOCYTE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; SEIZURE; SIDE EFFECT; T LYMPHOCYTE; THROMBOEMBOLISM; TREATMENT INDICATION; VASCULITIS;

EID: 0042466540     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)14184-0     Document Type: Conference Paper

References (140)

1. Arneil G.C. The nephrotic syndrome. Pediatr Clin North Am. 18:1971;547-559.
2. Srivastava T., Simon S.D., Alon U.S. High incidence of focal segmental glomerulosclerosis in nephrotic syndrome of childhood. Pediatr Nephrol. 13:1999;13-18.
3. Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at time of diagnosis - a report of the International Study of Kidney Disease in Children. Kidney Int 1978; 13: 159-65.
4. Gulati S., Sharma A.P., Sharma R.K., Gupta A. Changing trends of histopathology in childhood nephrotic syndrome. Am J Kidney Dis. 34:1999;646-650.
5. Bonilla-Felix M., Parra C., Dajani T., et al. Changing patterns in the histopathology of idiopathic nephrotic syndrome in children. Kidney Int. 55:1999;1885-1890.
6. Kari J.A. Changing trends of histopathology in childhood nephrotic syndrome in western Saudi Arabia. Saudi Med J. 23:2002;317-321.
7. Ingulli E., Tejani A. Racial differences in the incidence and renal outcome of idiopathic focal segmental glomerulosclerosis in children. Pediatr Nephrol. 5:1991;393-397.
8. Baqi N., Singh A., Balachandra S., et al. The paucity of minimal change disease in adolescents with primary nephrotic syndrome. Pediatr Nephrol. 12:1998;105-107.
9. Tryggvason K., Ruotsalainen V., Wartiovaara J. Discovery of the congenital nephrotic syndrome gene discloses the structure of the mysterious molecular sieve of the kidney. Int J Dev Biol. 43:1999;445-451.
10. Boute N., Gribouval O., Roselli S., et al. NPHS2, encoding the glomerular protein podocin, is mutated in autosomal recessive steroid-resistant nephrotic syndrome. Nat Genet. 24:2000;349-354.
11. Kaplan J.M., Kim S.H., North K.N., et al. Mutations in ACTN4, encoding alpha-actinin-4, cause familial focal segmental glomerulosclerosis. Nat Genet. 24:2000;251-256.
12. Winn M.P. Not all in the family: mutations of podocin in sporadic steroid- resistant nephrotic syndrome. J Am Soc Nephrol. 13:2002;577-579.
13. Pelletier J., Bruening W., Kashtan C.E., et al. Germline mutations in the Wilms' tumor suppressor gene are associated with abnormal urogenital development in Denys-Drash syndrome. Cell. 67:1991;437-447.
14. Guo J.K., Menke A.L., Gubler M.C., et al. WT1 is a key regulator of podocyte function: reduced expression levels cause crescentic glomerulonephritis and mesangial sclerosis. Hum Mol Genet. 11:2002;651-659.
15. Barbaux S., Niaudet P., Gubler M.C., et al. Donor splice-site mutations in WT1 are responsible for Frasier syndrome. Nat Genet. 17:1997;467-470.
16. Morello R., Lee B. Insight into podocyte differentiation from the study of human genetic disease: nail-patella syndrome and transcriptional regulation in podocytes. Pediatr Res. 51:2002;551-558.
17. Boerkoel C.F., Takashima H., John J., et al. Mutant chromatin remodeling protein SMARCAL1 causes Schimke immuno-osseous dysplasia. Nat Genet. 30:2002;215-220.
18. Shih N.Y., Li J., Karpitskii V., et al. Congenital nephrotic syndrome in mice lacking CD2-associated protein. Science. 286:1999;312-315.
19. Green G., Kim J., Winkler C., et al. Genetic polymorphisms in CD2AP are common in patients with glomerular disease. J Am Soc Nephrol. 13:2002;39. abstr.
20. Caridi G., Bertelli R., Carrea A., et al. Prevalence, genetics, and clinical features of patients carrying podocin mutations in steroid-resistant nonfamilial focal segmental glomerulosclerosis. J Am Soc Nephrol. 12:2001;2742-2746.
21. Karle S.M., Uetz B., Ronner V., Glaeser L., Hildebrandt F., Fuchshuber A. Novel mutations in NPHS2 detected in both familial and sporadic steroid-resistant nephrotic syndrome. J Am Soc Nephrol. 13:2002;388-393.
22. Frishberg Y., Rinat C., Megged O., Shapira E., Feinstein S., Raas-Rothschild A. Mutations in NPHS2 encoding podocin are a prevalent cause of steroid-resistant nephrotic syndrome among Israeli-Arab children. J Am Soc Nephrol. 13:2002;400-405.
23. Ito S., Ikeda M., Takata A., Kikuchi H., Hata J., Honda M. Nephrotic syndrome and end-stage renal disease with WT1 mutation detected at 3 years. Pediatr Nephrol. 13:1999;790-791.
24. Denamur E., Bocquet N., Baudouin V., et al. WT1 splice-site mutations are rarely associated with primary steroid-resistant focal and segmental glomerulosclerosis. Kidney Int. 57:2000;1868-1872.
25. Fuchshuber A., Gribouval O., Ronner V., et al. Clinical and genetic evaluation of familial steroid-responsive nephrotic syndrome in childhood. J Am Soc Nephrol. 12:2001;374-378.
26. Garin E.H. Circulating mediators of proteinuria in idiopathic minimal lesion nephrotic syndrome. Pediatr Nephrol. 14:2000;872-878.
27. Musante L., Candiano G., Zennaro C., et al. Humoral permeability factors in the nephrotic syndrome: a compendium and prospectus. J Nephrol. 14:(suppl 4):2001;S48-S50.
28. Schachter A.D., Harmon W.E. Single-center analysis of early recurrence of nephrotic syndrome following renal transplantation in children. Pediatr Transplant. 5:2001;406-409.
29. Savin V.J., Sharma R., Sharma M., et al. Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. N Engl J Med. 334:1996;878-883.
30. Esnault V.L., Besnier D., Testa A., et al. Effect of protein A immunoadsorption in nephrotic syndrome of various etiologies. J Am Soc Nephrol. 10:1999;2014-2017.
31. Kemper M.J., Wolf G., Muller-Wiefel D.E. Transmission of glomerular permeability factor from a mother to her child. N Engl J Med. 344:2001;386-387.
32. Carraro M., Caridi G., Bruschi M., et al. Serum glomerular permeability activity in patients with podocin mutations (NPHS2) and steroid-resistant nephrotic syndrome. J Am Soc Nephrol. 13:2002;1946-1952.
33. Candiano G., Musante L., Carraro M., et al. Apolipoproteins prevent glomerular albumin permeability induced in vitro by serum from patients with focal segmental glomerulosclerosis. J Am Soc Nephrol. 12:2001;143-150.
34. Koyama A., Fujisaki M., Kobayashi M., Igarashi M., Narita M. A glomerular permeability factor produced by human T cell hybridomas. Kidney Int. 40:1991;453-460.
35. Birmele B., Thibault G., Nivet H., de Agostini A., Girardin E.P. In vitro decrease of glomerular heparan sulfate by lymphocytes from idiopathic nephrotic syndrome patients. Kidney Int. 59:2001;913-922.
36. Wardle E.N. Minimal change nephrosis and allergy. Nephron. 74:1996;422-423.
37. Fuke Y., Endo M., Ohsawa I., et al. Implication of elevated serum IgE levels in minimal change nephrotic syndrome. Nephron. 91:2002;769-770.
38. Krause T.G., Koch A., Poulsen L.K., Kristensen B., Olsen O.R., Melbye M. Atopic sensitization among children in an arctic environment. Clin Exp Allergy. 32:2002;367-372.
39. Yap H.K., Cheung W., Murugasu B., Sim S.K., Seah C.C., Jordan S.C. Th1 and Th2 cytokine mRNA profiles in childhood nephrotic syndrome: evidence for increased IL-13 mRNA expression in relapse. J Am Soc Nephrol. 10:1999;529-537.
40. Frank C, Herrmann M, Fernandez S, et al. Dominant T cells in idiopathic nephrotic syndrome of childhood. Kidney Int 2000; 57: 510-07.
41. Matsumoto K., Kanmatsuse K. Augmented interleukin-18 production by peripheral blood monocytes in patients with minimal-change nephrotic syndrome. Am J Nephrol. 21:2001;20-27.
42. Cunard R., Kelly C.J. T cells and minimal change disease. J Am Soc Nephrol. 13:2002;1409-1411.
43. Lama G., Luongo I., Tirino G., Borriello A., Carangio C., Salsano M.E. T-lymphocyte populations and cytokines in childhood nephrotic syndrome. Am J Kidney Dis. 39:2002;958-965.
44. Sahali D., Pawlak A., Le Gouvello S., et al. Transcriptional and post-transcriptional alterations of IκBα in active minimal-change nephrotic syndrome. J Am Soc Nephrol. 12:2001;1648-1658.
45. Winston J.A., Bruggeman L.A., Ross M.D., et al. Nephropathy and establishment of a renal reservoir of HIV type 1 during primary infection. N Engl J Med. 344:2001;1979-1984.
46. Tanawattanacharoen S., Falk R.J., Jennette J.C., Kopp J.B. Parvovirus B19 DNA in kidney tissue of patients with focal segmental glomerulosclerosis. Am J Kidney Dis. 35:2000;1166-1174.
47. Li R.M., Branton M.H., Tanawattanacharoen S., Falk R.A., Jennette J.C., Kopp J.B. Molecular identification of SV40 infection in human subjects and possible association with kidney disease. J Am Soc Nephrol. 13:2002;2320-2330.
48. Stehman-Breen C., Alpers C.E., Fleet W.P., Johnson R.J. Focal segmental glomerular sclerosis among patients infected with hepatitis C virus. Nephron. 81:1999;37-40.
49. Humphreys M.H. Mechanisms and management of nephrotic edema. Kidney Int. 45:1994;266-281.
50. Vande Walle J., Donckerwolcke R., Boer P., van Isselt H.W., Koomans H.A., Joles J.A. Blood volume, colloid osmotic pressure and F-cell ratio in children with the nephrotic syndrome. Kidney Int. 49:1996;1471-1477.
51. Geers A.B., Koomans H.A., Boer P., Dorhout Mees E.J. Plasma and blood volumes in patients with the nephrotic syndrome. Nephron. 38:1984;170-173.
52. Dorhout Mees E.J., Geers A.B., Koomans H.A. Blood volume and sodium retention in the nephrotic syndrome: a controversial pathophysiological concept. Nephron. 36:1984;201-211.
53. Koomans H.A., Geers A.B., vd Meiracker A.H., Roos J.C., Boer P., Dorhout Mees E.J. Effects of plasma volume expansion on renal salt handling in patients with the nephrotic syndrome. Am J Nephrol. 4:1984;227-234.
54. Peterson C., Madsen B., Perlman A., Chan A.Y., Myers B.D. Atrial natriuretic peptide and the renal response to hypervolemia in nephrotic humans. Kidney Int. 34:1988;825-831.
55. Palmer B.F., Alpern R.J. Pathogenesis of edema formation in the nephrotic syndrome. Kidney Int Suppl. 59:1997;S21-S27.
56. Ichikawa I., Rennke H.G., Hoyer J.R., et al. Role for intrarenal mechanisms in the impaired salt excretion of experimental nephrotic syndrome. J Clin Invest. 71:1983;91-103.
57. Usberti M., Gazzotti R.M., Poiesi C., D'Avanzo L., Ghielmi S. Considerations on the sodium retention in nephrotic syndrome. Am J Nephrol. 15:1995;38-47.
58. Schrier R.W., Fassett R.G. A critique of the overfill hypothesis of sodium and water retention in the nephrotic syndrome. Kidney Int. 53:1998;1111-1117.
59. Vande Walle J.G., Donckerwolcke R.A. Pathogenesis of edema formation in the nephrotic syndrome. Pediatr Nephrol. 16:2001;283-293.
60. Querfeld U. Should hyperlipidemia in children with the nephrotic syndrome be treated? Pediatr Nephrol. 13:1999;77-84.
61. Vaziri N.D., Liang K. Up-regulation of acyl-coenzyme A:cholesterol acyltransferase (ACAT) in nephrotic syndrome. Kidney Int. 61:2002;1769-1775.
62. Shearer G.C., Kaysen G.A. Proteinuria and plasma compositional changes contribute to defective lipoprotein catabolism in the nephrotic syndrome by separate mechanisms. Am J Kidney Dis. 37:(suppl 2):2001;S119-S122.
63. Shearer G.C., Stevenson F.T., Atkinson D.N., Jones H., Staprans I., Kaysen G.A. Hypoalbuminemia and proteinuria contribute separately to reduced lipoprotein catabolism in the nephrotic syndrome. Kidney Int. 59:2001;179-189.
64. Nakahara C., Kobayashi K., Hamaguchi H., Kanemoto K., Kashiwagi R., Matsui A. Plasma lipoprotein (a) levels in children with minimal lesion nephrotic syndrome. Pediatr Nephrol. 13:1999;657-661.
65. Webb N.J., Lewis M.A., Iqbal J., Smart P.J., Lendon M., Postlethwaite R.J. Childhood steroid-sensitive nephrotic syndrome: does the histology matter? Am J Kidney Dis. 27:1996;484-488.
66. Gulati S., Sharma A.P., Sharma R.K., Gupta A., Gupta R.K. Do current recommendations for kidney biopsy in nephrotic syndrome need modifications? Pediatr Nephrol. 17:2002;404-408.
67. Cattran D.C. Idiopathic membranous glomerulonephritis. Kidney Int. 59:2001;1983-1994.
68. Ekka B.K., Bagga A., Srivastava R.N. Single- versus divided-dose prednisolone therapy for relapses of nephrotic syndrome. Pediatr Nephrol. 11:1997;597-599.
69. The primary nephrotic syndrome in children: identification of patients with minimal change nephrotic syndrome from initial response to prednisone - a report of the International Study of Kidney Disease in Children. J Pediatr 1981; 98: 561-64.
70. Ehrich J.H., Brodehl J. Long versus standard prednisone therapy for initial treatment of idiopathic nephrotic syndrome in children: Arbeitsgemeinschaft fur Padiatrische Nephrologie. Eur J Pediatr. 152:1993;357-361.
71. Hodson E.M., Knight J.F., Willis N.S., Craig J.C. Corticosteroid therapy in nephrotic syndrome: a meta-analysis of randomised controlled trials. Arch Dis Child. 83:2000;45-51.
72. Hogg R.J., Portman R.J., Milliner D., Lemley K.V., Eddy A., Ingelfinger J. Evaluation and management of proteinuria and nephrotic syndrome in children: recommendations from a pediatric nephrology panel established at the National Kidney Foundation conference on proteinuria, albuminuria, risk, assessment, detection, and elimination (PARADE). Pediatrics. 105:2000;1242-1249.
73. Durkan A.M., Hodson E.M., Willis N.S., Craig J.C. Immunosuppressive agents in childhood nephrotic syndrome: a meta-analysis of randomized controlled trials. Kidney Int. 59:2001;1919-1927.
74. Bargman J.M. Management of minimal lesion glomerulonephritis: evidence-based recommendations. Kidney Int Suppl. 70:1999;S3-S16.
75. Kemper M.J., Altrogge H., Ludwig K., Timmermann K., Muller-Wiefel D.E. Unfavorable response to cyclophosphamide in steroid-dependent nephrotic syndrome. Pediatr Nephrol. 14:2000;772-775.
76. Latta K., von Schnakenburg C., Ehrich J.H. A meta-analysis of cytotoxic treatment for frequently relapsing nephrotic syndrome in children. Pediatr Nephrol. 16:2001;271-282.
77. Gulati S., Pokhariyal S., Sharma R.K., et al. Pulse cyclophosphamide therapy in frequently relapsing nephrotic syndrome. Nephrol Dial Transplant. 16:2001;2013-2017.
78. Rivkees S.A., Crawford J.D. The relationship of gonadal activity and chemotherapy-induced gonadal damage. JAMA. 259:1988;2123-2125.
79. Meyrier A. Treatment of idiopathic nephrotic syndrome with cyclosporine A. J Nephrol. 10:1997;14-24.
80. Hoyer P.F., Krull F., Brodehl J. Cyclosporin in frequently relapsing minimal change nephrotic syndrome. Lancet. 2:1986;335.
81. Niaudet P., Habib R. Cyclosporine in the treatment of idiopathic nephrosis. J Am Soc Nephrol. 5:1994;1049-1056.
82. Hulton S.A., Neuhaus T.J., Dillon M.J., Barratt T.M. Long-term cyclosporin A treatment of minimal-change nephrotic syndrome of childhood. Pediatr Nephrol. 8:1994;401-403.
83. Gregory M.J., Smoyer W.E., Sedman A., et al. Long-term cyclosporine therapy for pediatric nephrotic syndrome: a clinical and histologic analysis. J Am Soc Nephrol. 7:1996;543-549.
84. Iijima K., Hamahira K., Tanaka R., et al. Risk factors for cyclosporine-induced tubulointerstitial lesions in children with minimal change nephrotic syndrome. Kidney Int. 61:2002;1801-1805.
85. Levamisole for corticosteroid-dependent nephrotic syndrome in childhood: British Association for Paediatric Nephrology. Lancet 1991; 337: 1555-57.
86. Alsaran K., Grisaru S., Stephens D., Arbus G. Levamisole vs. cyclophosphamide for frequently-relapsing steroid- dependent nephrotic syndrome. Clin Nephrol. 56:2001;289-294.
87. Yoshioka K., Ohashi Y., Sakai T., et al. A multicenter trial of mizoribine compared with placebo in children with frequently relapsing nephrotic syndrome. Kidney Int. 58:2000;317-324.
88. Choi M.J., Eustace J.A., Gimenez L.F., et al. Mycophenolate mofetil treatment for primary glomerular diseases. Kidney Int. 61:2002;1098-1114.
89. Melvin T., Sibley R., Michael A.F. Nephrotic syndrome. Tune B.M., Mendoza S.A. Contemporary issues in nephrology: pediatric nephrology. 1984;191-230 Churchill Livingstone, New York.
90. Tarshish P., Tobin J.N., Bernstein J., Edelmann C.M. Jr. Cyclophosphamide does not benefit patients with focal segmental glomerulosclerosis: a report of the International Study of Kidney Disease in Children. Pediatr Nephrol. 10:1996;590-593.
91. Rennert W.P., Kala U.K., Jacobs D., Goetsch S., Verhaart S. Pulse cyclophosphamide for steroid-resistant focal segmental glomerulosclerosis. Pediatr Nephrol. 13:1999;113-116.
92. Lieberman K.V., Tejani A. A randomized double-blind placebo-controlled trial of cyclosporine in steroid-resistant idiopathic focal segmental glomerulosclerosis in children. J Am Soc Nephrol. 7:1996;56-63.
93. Ponticelli C., Rizzoni G., Edefonti A., et al. A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome. Kidney Int. 43:1993;1377-1384.
94. Niaudet P. Treatment of childhood steroid-resistant idiopathic nephrosis with a combination of cyclosporine and prednisone. French Society of Pediatric Nephrology. J Pediatr. 125:1994;981-986.
95. Cattran D.C., Appel G.B., Hebert L.A., et al. A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group. Kidney Int. 56:1999;2220-2226.
96. Ingulli E., Tejani A. Severe hypercholesterolemia inhibits cyclosporin A efficacy in a dose-dependent manner in children with nephrotic syndrome. J Am Soc Nephrol. 3:1992;254-259.
97. Burgess E. Management of focal segmental glomerulosclerosis: evidence-based recommendations. Kidney Int Suppl. 70:1999;S26-S32.
98. McCauley J., Shapiro R., Ellis D., Igdal H., Tzakis A., Starzl T.E. Pilot trial of FK 506 in the management of steroid-resistant nephrotic syndrome. Nephrol Dial Transplant. 8:1993;1286-1290.
99. Schweda F., Liebl R., Riegger G.A., Kramer B.K. Tacrolimus treatment for steroid- and cyclosporin-resistant minimal-change nephrotic syndrome. Nephrol Dial Transplant. 12:1997;2433-2435.
100. Mendoza S.A., Tune B.M. Treatment of childhood nephrotic syndrome. J Am Soc Nephrol. 3:1992;889-894.
101. Kirpekar R., Yorgin P.D., Tune B.M., Kim M.K., Sibley R.K. Clinicopathologic correlates predict the outcome in children with steroid-resistant idiopathic nephrotic syndrome treated with pulse methylprednisolone therapy. Am J Kidney Dis. 39:2002;1143-1152.
102. Feld S.M., Figueroa P., Savin V., et al. Plasmapheresis in the treatment of steroid-resistant focal segmental glomerulosclerosis in native kidneys. Am J Kidney Dis. 32:1998;230-237.
103. Dantal J., Godfrin Y., Koll R., et al. Antihuman immunoglobulin affinity immunoadsorption strongly decreases proteinuria in patients with relapsing nephrotic syndrome. J Am Soc Nephrol. 9:1998;1709-1715.
104. Bosch T., Wendler T. Extracorporeal plasma treatment in primary and recurrent focal segmental glomerular sclerosis: a review. Ther Apher. 5:2001;155-160.
105. Stiles K.P., Abbott K.C., Welch P.G., Yuan C.M. Effects of angiotensin-converting enzyme inhibitor and steroid therapy on proteinuria in FSGS: a retrospective study in a single clinic. Clin Nephrol. 56:2001;89-95.
106. Lama G., Luongo I., Piscitelli A., Salsano M.E. Enalapril: antiproteinuric effect in children with nephrotic syndrome. Clin Nephrol. 53:2000;432-436.
107. Gaedeke J., Noble N.A., Border W.A. Angiotensin II and progressive renal insufficiency. Curr Hypertens Rep. 4:2002;403-407.
108. Aros C., Remuzzi G. The renin-angiotensin system in progression, remission and regression of chronic nephropathies. J Hypertens. 20:(suppl 3):2002;S45-S53.
109. Soliday E., Grey S., Lande M.B. Behavioral effects of corticosteroids in steroid-sensitive nephrotic syndrome. Pediatrics. 104:1999;e51.
110. Feinstein E.I., Chesney R.W., Zelikovic I. Peritonitis in childhood renal disease. Am J Nephrol. 8:1988;147-165.
111. Minimal change nephrotic syndrome in children: deaths during the first 5 to 15 years' observation: report of the International Study of Kidney Disease in Children. Pediatrics 1984; 73: 497-501.
112. Patiroglu T., Melikoglu A., Dusunsel R. Serum levels of C3 and factors I and B in minimal change disease. Acta Paediatr Jpn. 40:1998;333-336.
113. Overturf G.D. American Academy of Pediatrics,. Committee on Infectious Diseases, technical report: prevention of pneumococcal infections, including the use of pneumococcal conjugate and polysaccharide vaccines and antibiotic prophylaxis. Pediatrics. 106:2000;367-376.
114. McIntyre P., Craig J.C. Prevention of serious bacterial infection in children with nephrotic syndrome. J Paediatr Child Health. 34:1998;314-317.
115. Tain Y.L., Lin G., Cher T.W. Microbiological spectrum of septicemia and peritonitis in nephrotic children. Pediatr Nephrol. 13:1999;835-837.
116. Varicella zoster infections. In: Pickering L, ed. 2000 red book: report of the Committee on Infectious Diseases, 25th edn. Elk Grove Village, IL: American Academy of Pediatrics; 2000: 26-31.
117. Quien R.M., Kaiser B.A., Deforest A., Polinsky M.S., Fisher M., Baluarte H.J. Response to the varicella vaccine in children with nephrotic syndrome. J Pediatr. 131:1997;688-690.
118. Alpay H., Yildiz N., Onar A., Temizer H., Ozcay S. Varicella vaccination in children with steroid-sensitive nephrotic syndrome. Pediatr Nephrol. 17:2002;181-183.
119. Goldstein S.L., Somers M.J., Lande M.B., Brewer E.D., Jabs K.L. Acyclovir prophylaxis of varicella in children with renal disease receiving steroids. Pediatr Nephrol. 14:2000;305-308.
120. Sagripanti A., Barsotti G. Hypercoagulability, intraglomerular coagulation, and thromboembolism in nephrotic syndrome. Nephron. 70:1995;271-281.
121. Citak A., Emre S., Sairin A., Bilge I., Nayir A. Hemostatic problems and thromboembolic complications in nephrotic children. Pediatr Nephrol. 14:2000;138-142.
122. Andrew M., Michelson A.D., Bovill E., Leaker M., Massicotte M.P. Guidelines for antithrombotic therapy in pediatric patients. J Pediatr. 132:1998;575-588.
123. Feinstein S., Becker-Cohen R., Algur N., et al. Erythropoietin deficiency causes anemia in nephrotic children with normal kidney function. Am J Kidney Dis. 37:2001;736-742.
124. Vaziri N.D. Erythropoietin and transferrin metabolism in nephrotic syndrome. Am J Kidney Dis. 38:2001;1-8.
125. Ordonez J.D., Hiatt R.A., Killebrew E.J., Fireman B.H. The increased risk of coronary heart disease associated with nephrotic syndrome. Kidney Int. 44:1993;638-642.
126. Silva J.M., Oliveira E.A., Marino V.S., et al. Premature acute myocardial infarction in a child with nephrotic syndrome. Pediatr Nephrol. 17:2002;169-172.
127. Gheith O.A., Sobh M.A., Mohamed K.E., et al. Impact of treatment of dyslipidemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome. Nephron. 91:2002;612-619.
128. Dogra G.K., Watts G.F., Herrmann S., Thomas M.A., Irish A.B. Statin therapy improves brachial artery endothelial function in nephrotic syndrome. Kidney Int. 62:2002;550-557.
129. Wheeler D.C. Lipid abnormalities in the nephrotic syndrome: the therapeutic role of statins. J Nephrol. 14:(suppl 4):2001;S70-S75.
130. Coleman J.E., Watson A.R. Hyperlipidaemia, diet and simvastatin therapy in steroid-resistant nephrotic syndrome of childhood. Pediatr Nephrol. 10:1996;171-174.
131. Sanjad S.A., al-Abbad A., al-Shorafa S. Management of hyperlipidemia in children with refractory nephrotic syndrome: the effect of statin therapy. J Pediatr. 130:1997;470-474.
132. Auwerx J., De Keyser L., Bouillon R., De Moor P. Decreased free 1,25-dihydroxycholecalciferol index in patients with the nephrotic syndrome. Nephron. 42:1986;231-235.
133. Freundlich M., Bourgoignie J.J., Zilleruelo G., Abitbol C., Canterbury J.M., Strauss J. Calcium and vitamin D metabolism in children with nephrotic syndrome. J Pediatr. 108:1986;383-387.
134. Malluche H.H., Goldstein D.A., Massry S.G. Osteomalacia and hyperparathyroid bone disease in patients with nephrotic syndrome. J Clin Invest. 63:1979;494-500.
135. Chadha V., Alon U.S. Bilateral nephrectomy reverses hypothyroidism in congenital nephrotic syndrome. Pediatr Nephrol. 13:1999;209-211.
136. Koomans H.A. Pathophysiology of acute renal failure in idiopatic nephrotic syndrome. Nephrol Dial Transplant. 16:2001;221-224.
137. Kabuki N., Okugawa T., Hayakawa H., Tomizawa S., Kasahara T., Uchiyama M. Influence of age at onset on the outcome of steroid-sensitive nephrotic syndrome. Pediatr Nephrol. 12:1998;467-470.
138. Constantinescu A.R., Shah H.B., Foote E.F., Weiss L.S. Predicting first-year relapses in children with nephrotic syndrome. Pediatrics. 105:2000;492-495.
139. Yap H.K., Han E.J., Heng C.K., Gong W.K. Risk factors for steroid dependency in children with idiopathic nephrotic syndrome. Pediatr Nephrol. 16:2001;1049-1052.
140. Tarshish P., Tobin J.N., Bernstein J., Edelmann C.M. Jr. Prognostic significance of the early course of minimal change nephrotic syndrome: report of the International Study of Kidney Disease in Children. J Am Soc Nephrol. 8:1997;769-776.